Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma based upon standard criteria~* Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of \> 1 g/dl and/or urine monoclonal immunoglobulin spike of \> 200mg/24 hours.~* Karnofsky performance status of \> 60~* Hemoglobin \> 8.0 g/dL~* AST (SGOT) \< 3 x ULN~* ALT \< 3 x ULN~* Total bilirubin \< 2 x ULN~* Is infertile or is practicing an adequate form of contraception~* 18 years of age or older~Exclusion Criteria:~* Prior treatment with systemic chemotherapy~* Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes~* Plasma cell leukemia~* Calculated or measured creatinine clearance \< 30 mL/minute within 14 days of enrollment~* Grade 2 or greater peripheral neuropathy~* Hypersensitivity to bortezomib, boron or mannitol~* Severe hypercalcemia~* HIV positive~* Known active hepatitis B or C~* New York Hospital Association Class III or IV heart failure~* Second malignancy requiring concurrent treatment~* Other serious medical or psychiatric illness~* Pregnant women~* Dialysis dependent patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bortezomib (Type: EXPERIMENTAL): Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).